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Abstract
Background—Human immunodeficiency virus (HIV)-associated cryptococcal meningitis (CM) 
is characterized by high fungal burden and limited leukocyte trafficking to cerebrospinal fluid 
(CSF). The immunopathogenesis of CM immune reconstitution inflammatory syndrome (IRIS) 
after initiation of antiretroviral therapy at the site of infection is poorly understood.
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Methods—We characterized the lineage and activation status of mononuclear cells in blood and 
CSF of HIV-infected patients with noncryptococcal meningitis (NCM) (n = 10), those with CM at 
day 0 (n = 40) or day 14 (n = 21) of antifungal therapy, and those with CM-IRIS (n = 10).
Results—At diagnosis, highly activated CD8+ T cells predominated in CSF in both CM and 
NCM. CM-IRIS was associated with an increasing frequency of CSF CD4+ T cells (increased 
from 2.2% to 23%; P = .06), a shift in monocyte phenotype from classic to an intermediate/
proinflammatory, and increased programmed death ligand 1 expression on natural killer cells 
(increased from 11.9% to 61.6%, P = .03). CSF cellular responses were distinct from responses in 
peripheral blood.
Conclusions—After CM, T cells in CSF tend to evolve with the development of IRIS, with 
increasing proportions of activated CD4+ T cells, migration of intermediate monocytes to the CSF, 
and declining fungal burden. These changes provide insight into IRIS pathogenesis and could be 
exploited to more effectively treat CM and prevent CM-IRIS.
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Cryptococcus neoformans, the most common cause of adult meningitis in sub-Saharan 
Africa [1], causes 20%–25% of AIDS-related deaths [2, 3]. Despite this substantial burden 
of disease with cryptococcal menin-gitis (CM), the mechanisms of immune defense are not 
well characterized, especially at the site of infection in the human central nervous system 
(CNS). Cryptococcus is proposed to cross the blood-brain barrier through 3 mechanisms: via 
endothelial cells when tight junctions are damaged or weakened (paracellular) [4], via brain 
endothelial cells (transcytosis) [5],or within infected monocytes or macrophages (Trojan 
horse) [6]. Aerosol infection of mice with Cryptococcus spores elicits a self-limited 
subclinical pneumonia, accompanied sequentially by local recognition of the fungus by 
alveolar macrophages and neutrophils, then by monocytes and finally expansion of 
Cryptococcus-specific CD4+ and CD8+ T cells [7, 8], which parallels the 
immunopathogenesis in the cerebrospinal fluid (CSF) with meningitis [9]. Similarly, in 
healthy individuals, the initial immune response in the lung involves fungal recognition by 
innate immune cells and subsequent expansion of Cryptococcus-specific CD4+ T cells to 
control the infection [7]. In scenarios involving immunodeficiency, such as human 
immunodeficiency virus (HIV) infection, depletion of CD4+ T cells increases the likelihood 
of Cryptococcus invasion of the blood-brain barrier to cause meningoencephalitis [8, 10].
The phenotype of infiltrating immune cells at the site of infection in humans with CM is 
poorly characterized. Tissues from patients with CM but without HIV or other 
immunodeficiency show robust granulomatous inflammatory responses [11] and CSF 
pleocytosis [12-14], whereas among those with HIV coinfection, CSF cell counts are lower 
and predominantly CD8+ rather than CD4+ T cells [15,16].In the presence of HIV 
coinfection, up to 25% of patients with CM treated with antifungal and antiretroviral therapy 
(ART) [17] will experience paradoxical deterioration due to immune reconstitution 
inflammatory syndrome (IRIS) despite mycologic and virologic suppression [18].IRIS may 
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manifest as relapsing aseptic meningitis, increased intracranial pressure, new focal 
neurologic signs, intracranial cryptococcomas, lymphadenopathy, and development of 
abscesses [19-22]. In the majority of patients with IRIS, fungal burden decreases with 
antifungal therapy as evidenced by decreased cryptococcal antigen titers and sterile CSF 
microbiologic cultures [17, 22,23]; however, the target tissue-specific cellular profile and 
activation status in CSF remain poorly characterized.
In this study, we characterized the lineage, activation, and differentiation of mononuclear 
cells that migrate across the blood-brain barrier in HIV-infected patients upon initial 
presentation with CM and at the time of CM-IRIS to better understand the localized host 
response in IRIS to C. neoformans in this immunocompromised population.
MATERIALS AND METHODS
Study Subjects
Study participants were prospectively enrolled in the (1) Cryptococcal Optimal 
Antiretroviral Timing (COAT) trial (Clinicaltrials.gov: NCT01075152), a randomized 
strategy trial assessing the optimal timing of ART initiation in CM [24], or in the (2) 
Neurological Outcomes on ART (NOAT) study, a prospective observational cohort of HIV-
infected persons with clinical meningitis [25]. CSF and blood were collected from subjects 
screened sequentially at Mulago National Referral Hospital in Kampala, Uganda. Inclusion 
criteria for both cohorts included documented HIV infection, being ART naive, age ≥18 
years, and clinical evidence of meningitis. Written informed consent was obtained from 
participants or their surrogates. Institutional review board approval was obtained from 
Makerere University, the University of Minnesota, and the Uganda National Council for 
Science and Technology.
Lumbar punctures were performed in hospitalized patients on presentation and samples 
evaluated with standard testing for bacteria (Gram stain and culture) and Cryptococcus 
culture and cryptococcal antigen conducted on site. Further molecular evaluation for viruses 
and fungi was performed on cryopreserved CSF (Supplementary Methods). Approximately 
10 mL of CSF were centrifuged at 400g for 5 minutes to pellet cells, then cryopreserved in 
Roswell Park Memorial Institute medium supplemented with fetal bovine serum (20%), 
dimethyl sulfoxide (10%), and penicillin-streptomycin (1%) with storage in liquid nitrogen 
after controlled freezing.
A diagnosis of definite/probable/possible CM-IRIS was made according to the published 
consensus case definition [18], with external adjudication by a 3-physician panel.
CSF Flow Cytometry
Polychromatic flow cytometry was performed on thawed CSF cell samples collected at 
screening (day 0; n = 40), day 14 (n = 21) of antifungal therapy, and at the CM-IRIS event 
(n = 10). Immunophenotyping of CSF white blood cells (WBCs) was performed based on 
panleukocyte marker CD45+ (Figure 1A and B), differential gating based on size and 
granularity (Figure 1C), and lineage markers for T cells (CD3+/CD4+ or CD3+/CD4−), the 
latter referred to as CD8+ T cells because >90% of this subset are CD8+, natural killer (NK) 
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cell (CD3−4−CD56+CD16+/−) subsets (Figure 1E), monocytes (CD3−CD4lowCD56−) and 
monocyte subsets based on expression of CD14 and CD16 (Figure 1F), as defined in 
Supplementary Methods. We characterized activation by expression of HLA-DR for CD3+ 
and NK cells and programmed death ligand 1 (PD-L1) for each lineage. Cells were stained 
with commercial monoclonal antibodiesfluorochrome (clone) reactive with CD3V500 (clone 
UCHT1), CD4V450 (clone RPA-T4; BD Horizon); CD14FITC (clone M5E2, CD45APC–Cy7 
clone 2D1, CD274/PD-L1PE (clone MIH1, CD56PerCPCy5.5 (clone B159, CD8APC-Cy7 
(clone SK1; BD Pharmingen); HLA-DRPE-Cy7 (clone LN3; eBioscience) and CD16APC 
(clone 3G8; Biolegend) (where APC represents allophycocyanin; Cy5.5, cyanine 5.5; Cy7, 
cyanine 7; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCP, peridinin 
chlorophyll). Fluorescence minus 1 controls were prepared on blood samples to set gates for 
HLA-DR and PD-L1.
Statistical Analysis
Data were analyzed using SAS software (version 9.3; SAS Institute). Comparisons of paired 
groups were evaluated with the nonparametric Wilcoxon signed rank test. Cell phenotype 
and activation variables were compared at different time points with the nonparametric 
Mann–Whitney rank sum test. Statistical significance was defined at P < .05.
RESULTS
Participants
Sixty-three HIV-infected subjects presenting with symptoms of meningitis consented to 
have a lumbar puncture performed and were entered into this study. Of these, CM was 
diagnosed in 46 subjects, a control group of 10 subjects had noncryptococcal meningitis 
(NCM) and nonbacterial meningitis, and 7 subjects had normal CSF. Age, sex, and 
neurologic symptoms were similar in the CM and NCM groups (Table 1). All subjects with 
CM began ART within 6 weeks of diagnosis (zidovudine, lamivudine, and efavirenz) after 
induction therapy with intravenous amphotericin B (0.7–1 mg/kg/d) for 2 weeks and oral 
fluconazole (800 mg/d) for approximately 5 weeks, later decreased to 400 mg/d for 8 weeks 
and 200 mg/d thereafter. Among the 46 subjects with CM, 10 (22%) were adjudicated as 
having CM-IRIS during follow-up (Figure 2), 22 (48%) survived without CM-IRIS, and 14 
(30%) died within 3 months of CM diagnosis. Forty subjects with CM had sufficient 
baseline CSF specimens available for analysis at baseline, and 21 subjects at day 14. Among 
subjects with CM-IRIS, 6 of 10 had CSF cells analyzed at both CM diagnosis and CM-IRIS, 
and 4 of these 6 subjects had CSF cells analyzed at day 14 of CM treatment. The median 
time from ART initiation to IRIS was 110 days (interquartile range [IQR], 73–227 days).
Cryptococcal antigen titers decreased significantly from diagnosis (day 0) to day 14 of CM 
amphotericin therapy (P < .001) as did the number of cryptococcal colony-forming units per 
milliliter during this period (P < .001) (Table 1). Subjects presenting with CM had severe 
CD4+ T-cell depletion in peripheral blood and viral load, decreased by approximately 3 
log10 copies/mL from ART initiation to time of IRIS (Table 1).
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Mononuclear Cell Phenotype in CSF With CM Versus NCM
A microbiologic diagnosis was established in 10 subjects with NCM (Figure 2). The 
numbers of CSF leukocytes of 40 adults with CM at diagnosis did not differ from those in 
10 patients with NCM (P = .57) (Table 1). CD8+ (CD3+CD4−) T cells constituted the 
predominant cell type in CSF among subjects with CM at day 0 (median, 72%; IQR, 57%–
78%) and day 14 (median, 78%; IQR, 70%–86%) of antifungal therapy, comparable to that 
in subjects with NCM at presentation. At baseline, CD4+ T cells were higher among subjects 
with NCM (median, 13.6%; IQR, 1%–6%) compared with the CM group (median, 3.5%; 
IQR, 5%–29%; P = .01), whereas NK cells were present at comparable frequencies in 
patients with or without CM.
The CSF WBC counts (decreased during 2 weeks of antifungal therapy, from a median of 25 
cells/μL (IQR, 16–83 cells/μL) at day 0 to 8 cells/μL (IQR, 3–19 cells/μL) at day 14 (P < .
001), as did the proportion of CD4+ T cells. A small minority population of monocytes was 
present in CSF at both time points. The majority of monocytes were of the classic phenotype 
(or subset) (CD14++CD16−), with a median of 68% (IQR, 52%–89%) at day 0 of CM 
treatment, 73% (IQR, 57%–97%) at day 14, and 40% for NCM (IQR, 17%–67%). NK-cell 
subsets defined by CD56 and CD16 expression were also similar in each group at baseline 
(data not shown).
Activation of Mononuclear Cells in CSF
The vast majority of CSF T cells and NK cells were activated in patients with or without 
CM meningitis, as determined by expression of HLA-DR (Figure 3). In contrast, the 
frequency of expression of PD-L1 on monocytes was high in both groups at baseline, but 
highest in the NCM group (Figure 3), and in both classic and intermediate monocyte subsets 
(data not shown). A similar increase in PD-L1 was evident on NK cells in the NCM 
population. The high frequency of HLA-DR expression on T cells and NK cells did not 
change significantly during CM treatment, nor did PD-L1 expression on monocytes and NK 
cells (Figure 3).
Lymphocyte Activation in CSF With CM-IRIS
Ten of 46 subjects (21%) with CM developed IRIS in the first 6 months of ART. Paired CSF 
samples were available from 6 of these subjects at both day 0 of CM treatment and at CM-
IRIS diagnosis (Tables 2 and 3). Neither CSF WBC count nor CSF protein values differed 
from day 0 to the time of IRIS. Although the high proportion of CD8+ T cells remained 
stable from treatment initiation to the time of CM-IRIS, the frequency of CD4+ T cells 
increased (albeit not significantly) during this period, whereas NK cells declined (P = .03). 
These changes in lineage distribution among the subjects with paired samples were 
consistent with those in the larger unmatched groups comparing lineage (data not shown) 
and NK-cell activation at day 14 of CM treatment and CM-IRIS (Supplementary Figure 3). 
HLA-DR expression on CD4+ and CD8+ T cells remained elevated but stable at CM-IRIS 
compared with day 0 (Table 2), whereas PD-L1 expression increased significantly on NK 
cells overall, particularly in the CD56dim NK-cell subset (terminally differentiated 
precursors of CD56bright NK cells).
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Although the proportion of monocytes in CSF was stable, these monocytes showed a 
striking maturation from the predominant CD14++CD16− classic subset at baseline to a more 
proinflammatory intermediate phenotype (CD14++CD16+) at IRIS (Table 3). Moreover, 
expression of PD-L1 on monocytes increased as well, particularly in the intermediate and 
nonclassic subsets (Supplementary Figures 1 and 2). This pattern of cell evolution with CM-
IRIS was recapitulated in the larger unmatched cohort comparing lineage and activation 
among 17 subjects at CM diagnosis and day 14 of CM treatment and 4 subjects at CM-IRIS 
diagnosis. Thus, although the absolute number of leukocytes at IRIS was similar to the 
number at initial CM, the cellular constituents did change, as did their activation status with 
CM-IRIS. We considered whether these changes were unique to the site of disease in the 
local CSF compartment or indicative of a more generalized systemic response with ART.
Cell Frequencies and Activation Differ Between Blood and CSF at CM-IRIS
At the time of CM-IRIS, the frequencies and activation of lymphocytes were distinctly 
different in CSF and blood. Although CD8+ T cells were the predominant cell type in the 2 
compartments, the proportion of CD4+ T cells was significantly higher in CSF at CM-IRIS 
than in blood (Figure 4). The median change in CD4+ T cells (from baseline to IRIS) in 
blood was 3.0% (IQR, 2.5%–4.5%), compared with 23% (IQR, 14%–28%) in CSF, (P = .
06), suggesting that a greater increase in the CD4+ T-cell change occurred in CSF compared 
with blood, although this difference was not statistically significant. We also found no 
significant correlation between the CD4+ T-cell changes in blood compared with those in 
CSF (r = 0.43; P = .43), suggesting that these CD4+ T-cell changes were independent and 
probably compartment specific.
Consistent with these differences, the classic subset (CD14++CD16−) comprised 86% of 
monocytes in blood (IQR, 83%–89%) but only 13% (IQR, 0%–28%) in CSF; intermediate 
monocytes had higher frequencies in CSF than in blood, suggesting that IRIS represents a 
localized response at the site of infection rather than a more generalized response to ART 
(Figure 4). In line with these disproportionate cell lineages, T-cell activation (by HLA-DR 
expression) was significantly greater on both CD4+ and CD8+ T cells in CSF compared with 
blood, as was PD-L1 expression on classic and intermediate monocytes (Figure 4). The 
more efficient cytokine NK subset, the CD56bright NK cells, tended to have higher 
frequencies in CSF than blood (data not shown). We demonstrate distinct phenotypic and 
activation changes involving both the adaptive and innate immune systems, which could 
play a role in the immunopathology occurring during CM-IRIS events.
DISCUSSION
We characterized the evolution of cellular infiltrates at the site of CM infection, the CSF, 
from the time of diagnosis when the host is most immunosuppressed, soon after ART 
initiation and as immune integrity is being restored at the time of CM-IRIS in patients with 
advanced HIV coinfection. The number of immune cells in the CSF was quite limited in 
these severely lymphopenic patients despite a high fungal burden, comparable to that in 
patients without CM. The predominance of highly activated but apparently ineffective CD8+ 
T cells at presentation was supplemented by an increasing number of activated CD4+ T cells 
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into the CSF as the fungal burden declined with antifungal therapy. The source of this 
enhanced immune integrity may be ART initiation as well as the evolving maturation of 
monocytes and the activation of both monocytes and NK cells in the CSF. However, a 
consequence of this proposed increased immune integrity at this local site may be the 
development of neurologic symptoms in the confined CNS compartment that manifest as 
CM-IRIS.
Both the low numbers of CSF cells and the predominance of CD8+ T cells in the CSF are 
consistent with those described else-where in murine models and human asymptomatic HIV 
infection [16, 26]. The low cell numbers could also be related to persisting cryptococcal 
antigen (at CM-IRIS), which is known to inhibit leukocyte migration by modulating 
expression of L-selectin on T cells [27, 28]. In contrast, healthy HIV-seronegative adults 
have very few cells in the CSF, and CD4+ T cells represent the majority of these few 
lymphocytes [16, 29]. Despite unremarkable changes in CSF profiles with antifungal 
treatment and ART initiation at 2 weeks, those who develop CM-IRIS show a nonsignificant 
increase in CSF CD4+ T cells and a statistically significant increase in the frequency of 
intermediate monocyte subsets. The associated increased expression of the 
immunosuppressive protein PD-L1 on both the monocyte and NK-cell subsets may reflect 
an exaggerated activated state. Indeed, PD-L1 is highly expressed on monocytes and 
macrophages during inflammatory conditions, such as septic shock and rheumatoid arthritis 
[30-32]. Alternatively, this ligand may serve as a counterregulatory mechanism to limit the 
increasingly exuberant CD4+ T-cell responses, which may drive monocyte maturation and 
activation, as well as stimulate NK-cell activity.
Missing from the development of this evolving paradigm are the ontogeny of CD4+ T cells, 
monocytes, NK cells, and their activation among patients who resolved their infections 
successfully with antifungal therapy and ART and those who died early in the course of this 
fungal infection. Characterizing the natural history of the immune response in the CSF from 
these latter groups over time would clarify whether CM-IRIS represents an overexuberant 
pathologic response to persistent antigen or the development of an increasingly normal or 
healthy functional response to cryptococcal antigens under the influence of ART-associated 
recovery of immune function.
Our results from matched CSF and peripheral blood analyses reveal that the CM-IRIS–
associated changes in cellular distribution, phenotype, and surface receptor/ligand 
expression in the CSF compartment are distinct from and more exuberant than those in the 
systemic circulation. Results from studies of IRIS syndromes with other infections do not 
provide this unique opportunity to study the immunopathology where these processes are 
actually occurring in real time. Indeed, as shown here, the characteristics of immune cells in 
the peripheral circulation, although convenient to sample and where cryptococcal antigen 
also persists, represent an inaccurate or certainly an incomplete view of responses to fungal 
and, likely, mycobacterial (eg, tuberculosis) [33]or viral (eg, hepatitis C) [34] antigens 
occurring at specific tissue sites, such as the CNS, lung, or liver, all common sites of IRIS.
During CM-IRIS, the changes in CSF cell lineages and activation profiles after the initiation 
of ART may represent an evolving and increasingly effective CM-specific response [35]. 
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The transition to or influx of intermediate monocytes and up-regulation of PD-L1 on 
CD56dim NK cells were findings unique to CM-IRIS. These changes, particularly among the 
monocyte subsets, were not a consequence of amphotericin B, which has 
immunomodulatory properties, because the changes were not reliably present from day 0 to 
day 14 of amphotericin therapy but rather occurred well after discontinuation of 
amphotericin [36].
Our observed increase in intermediate monocytes at CM-IRIS is compatible with the 
reported relative abundance of chemokines (including CCL2 and CCL3) that promote 
monocyte trafficking into the CSF [15] and elevated innate cytokines including interleukin 
1R, 6, and 8, tumor necrosis factor, and granulocyte–colony stimulating factor, which we 
have demonstrated elsewhere in blood and CSF [22, 37]. Moreover, the shift from classic 
(involved largely in phagocytosis and preferentially producing the immunosuppressive 
cytokine, interleukin 10) to proinflammatory intermediate monocytes (known to possess the 
highest expression of surface markers for antigen processing and presentation and produce 
the highest amounts of proinflammatory cytokines) probably represents a response to the 
inflammatory milieu present in the CNS during CM-IRIS. These changes in monocyte 
distribution in the CSF during CM-IRIS also support the data showing that intermediate 
monocytes contribute to an inflammatory systemic environment predisposing to serious non-
AIDS events through secretion of proinflammatory mediators [38]. The skewed distribution 
of monocyte subsets suggests involvement of the innate immune system in the dysregulated 
response during CM-IRIS, as proposed by Barber et al [39] and recently demonstrated in 
tuberculosis-associated IRIS [40]. Although the classic monocyte subset may replace 
intermediate monocytes with successful antifungal therapy [41], we identify the opposite 
trend when CM-IRIS develops, highlighting the distinct local environment in the setting of 
this paradoxical complication of ART.
The trend to increased frequency of CD4+ T cells from day 14 of CM treatment until the 
development of CM-IRIS may reflect peripheral immune recovery in response to ART, 
during which naive and memory T cells may preferentially traffic into the CNS [42, 43]. It is 
also plausible that the influx of CD4+ T cells may reflect an expansion of CNS-resident 
effector-memory CD4+ T cells, consistent with the observed trend to higher inter-leukin 7 
production with IRIS, in response to residual cryptococcal antigen as reported with other 
forms of IRIS, including tuberculosis-associated IRIS [44-46]. In either scenario, the milieu 
in CSF is clearly distinct from that in the blood in terms of cellular distributions and 
activation profiles. Further studies are needed to determine the antigen specificity of these 
CD4+ and CD8+ T cells in the CSF, which were not evaluated in our study. The small 
sample size was a limitation in drawing firm conclusions on associations between 
phenotype, activation and mortality. However, the multilineage characterization of cells in 
the CSF from the initiation of ART to the time of IRIS is an instructive feature of this study 
that requires validation in a larger cohort.
Antonelli and colleagues [46]have described high frequencies of HLA-DR+CD4+ T cells 
with increased expression of PD-1 on CD4+ and CD8+ T cells in blood during IRIS in the 
setting of diverse coinfections. Our data suggest that such activation is higher yet in the CSF 
compartment during CM-IRIS. A plausible hypothesis is that the interaction between PD-L1 
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on the innate cells with PD-1 expressed on T cells may support the initiation of a negative 
feedback response, to limit T-cell activation and the immunopathology triggered by 
exaggerated T-cell immune responses during CM-IRIS [22].
In conclusion, our findings in CSF support the hypothesis that, although immune responses 
appear attenuated at the time of presentation with CM among patients with very advanced 
HIV disease, both adaptive and innate immune axes participate in the immunopathogenesis 
of CM-IRIS. How the balance of adaptive immune activation and innate regulatory 
mechanisms are served by the apparent influx of highly activated CD4+ T cells and the 
evolution of classic to intermediate monocytes requires further investigation. We therefore 
hypothesize that future therapeutic intervention studies to treat or prevent CM-IRIS could 
exploit these distinct cellular changes as immunologic end points.
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Figure 1. 
Flow cytometry gating strategy for cerebrospinal fluid (CSF) cells. Analytic gating of the 
flow cytometry data. A, White blood cells in CSF were separated from cryptococcal cells 
using a CD45 gate. B, Neutrophils and debris were separated from CD45+ cells on the basis 
of forward-scatter area (FSC-A) and side-scatter area (SSC-A). C, Broad natural killer (NK) 
cell gate, monocyte gate, and lymphocyte populations were selected. D, CD3+ T-cell subset 
populations were identified. E, NK-cell subsets were then identified based on differential 
expression of CD16/56. F, Monocyte subsets were defined based on differential CD14/16 
expression. G, Activation by HLA-DR expression on T cells, here showing expression on 
CD4+ T cells. H, HLA-DR expression on NK cells, showing expression on the CD56bright 
subset. I, Programmed death ligand 1 (PD-L1) expression on NK cells, showing expression 
on CD56bright subset. J, PD-L1 expression on monocytes, showing expression on classic 
monocytes.
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Figure 2. 
Study flow diagram. Distribution of subjects with suspected meningitis and etiology of 
meningitis in a nested cohort of human immunodeficiency virus-infected subjects in the 
Cryptococcal Optimal Antiretroviral Timing (COAT) trial and Neurological Outcomes on 
ART (NOAT) study in Mulago National Referral Hospital, Kampala, Uganda. 
Abbreviations: CM, cryptococcal meningitis; CSF, cerebrospinal fluid; EBV, Epstein-Barr 
virus; IRIS, with immune reconstitution inflammatory syndrome.
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Figure 3. 
Cellular activation in cerebrospinal fluid (CSF) among subjects with cryptococcal 
meningitis (CM) and noncryptococcal meningitis (NCM). Activation of CD4+, CD8+, and 
natural killer (NK) cells in CSF is shown by HLA-DR expression and programmed death 
ligand 1 (PD-L1) expression on monocytes and NK cells. CSF was analyzed with flow 
cytometry at day 0 and day 14 of CM treatment among subjects with CM (n = 21) or NCM 
(n = 16) at meningitis diagnosis.
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Figure 4. 
Cell phenotype and activation in matched blood and cerebrospinal fluid (CSF) at diagnosis 
of cryptococcal meningitis with immune reconstitution inflammatory syndrome (CM-IRIS). 
Cell lineages in the CSF and peripheral blood compartments (top panel) and monocyte 
subsets (middle panel) are shown for 6 subjects at the diagnosis of CM-IRIS. The frequency 
of natural killer cells (not shown) was similar. Bottom panel shows HLA-DR expression on 
T cells and programmed death ligand 1 (PD-L1) expression on monocyte subsets.
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Table 1
Demographic Characteristics of HIV-Infected Subjects in Kampala, Uganda, at 
Enrollment With CM and NCM Meningitis and Day 14 of CM Therapya
Characteristic CM (n = 40) NCM (n = 10)b
Age, y 37 (30–40) 34 (31–36)
Females, No. (%) 25 (63) 4 (40)
Symptoms, No. (%)
 Headache 38 (95) 10 (100)
 Fever 31 (78) 10 (100)
 Neck pain 30 (75) 9 (90)
 Glasgow Coma Score <15c 13 (33) 8 (80)
3-mo mortality, No. (%) 14 (35) 4 (44)
Blood values at enrollment
 CD4+ T cells/μL 16 (6–70) 290 (51–557)d
 CD8+ T cells/μL 283 (177–428) 513 (210–1239)d
 CD4/CD8 ratio 0.08 (0.04–0.12) 0.56 (0.14–0.88)d
Plasma HIV RNA, log10 copies/mL
e
 Day 0 5.3 (4.8–5.4)
 IRIS event 2.6 (2.0–2.6)
CSF values at enrollment
 WBCs/μL 25 (16–83) 36 (11–678)
 LFA CrAg titerf
  Day 0 7200 (1512–8096) 0
  Day 14 1000 (512–2000) 0
 Protein, mg/dL 94 (62–187) 253 (156–352)
 CSF CD4/CD8 ratio 0.06 (0.03–0.12) 0.20 (0.05–0.72)
 Cryptococcal CFUs/mLg
  Day 0 180 000 (30 400–350 000) 0
  Day 14 0 (0–30) 0
Abbreviations: CFUs, colony-forming units in quantitative culture; CM, cryptococcal meningitis; CrAg, cryptococcal antigen; CSF, cerebrospinal 
fluid; HIV, human immunodeficiency virus; IRIS, immune reconstitution inflammatory syndrome; LFA, lateral flow assay; NCM, noncryptococcal 
meningitis; WBCs, white blood cells.
a
Data were available from 26 subjects. Unless otherwise specified, data represent medians (interquartile ranges).
bOf these subjects, 4 had Epstein Barr Virus in CSF, 2 had tuberculous meningitis, 1 had cerebral malaria, 1 had toxoplasmosis, and 2 had viral 
meningitis.
cGlasgow Coma Scores ranged from 4 to 15.
d
Twelve subjects did not have CD4/CD8 measured in the hospital.
J Infect Dis. Author manuscript; available in PMC 2015 May 15.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Meya et al. Page 17
eWilcoxon rank sum test was used to compare viral loads at CM diagnosis and at the IRIS event (P < .002).
f
Paired signed rank test was used to compare median CrAg titers at screening and at day 14 of CM treatment for 23 subjects (P < .001).
g
Paired signed rank test was used to compare median quantitative culture values at screening and at day 14 of CM treatment for 30 subjects (P < .
001).
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Table 2
CSF Parameters and Lymphocyte Phenotypes at CM Diagnosis and During CM-IRISa
Parameters and Phenotypes Day 0 of CM (n = 6) CM-IRIS Event (n = 6) P Valueb
WBCs/μL 18 (14.0–58.0) 17 (3.5–33.5) .31
CSF protein, mg/dL 91 (65–187) 20 (20–87) .31
CD4+ T cells, % 2.2 (0.9–6.4) 22.7 (16.5–25.8) .06
CD8+ T cells, % 63.6 (57.6–72.3) 66.1 (61.3–70.6) .31
CD4/CD8 ratio 0.04 (0.01–0.08) 0.33 (0.25–0.38) .09
HLA-DR expression,%
 CD4+ T cells 79.9 (70.6–94.5) 78.4 (72.5–79.5) .31
 CD8+ T cells 88.7 (87.7–92.7) 90.5 (89.5–91.7) .62
NK cells, % 6.6 (4.0–7.9) 0.8 (0.3–1.2)
.03c
NK-cell subset
 CD56bright 39.0 (31.7–49.2) 30.3 (10.2–43.4) .56
 CD56dim 49.6 (42.1–55.1) 46.3 (41.9–80.0) .31
 CD56− 6.6 (2.9–17.4) 8.0 (0.0–15.2) >.99
PD-L1 expression, %
 All NK cells 11.9 (8.0–25.3) 61.6 (44.3–100.0)
.03c
 CD56bright 17.9 (11.7–30.1) 49.2 (46.9–51.4) .16
 CD56dim 3.7 (2.0–16.1) 54.8 (36.9–100.0)
.03c
 CD56− 20.2 (16.7–34.0) 52.8 (0.0–63.6) .44
Abbreviations: CM, cryptococcal meningitis; CSF, cerebrospinal fluid; IRIS, immune reconstitution inflammatory syndrome; NK, natural killer; 
PD-L1, programmed death ligand 1; WBCs, white blood cells.
aAll data represent medians (interquartile ranges).
b
Medians were compared using a signed rank test for paired observations.
cSignificant difference (P < .05).
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Table 3
Monocyte Subsets and Activation in CSF at CM Diagnosis and CM-IRIS Eventsa
Monocyte At CM Diagnosis (n = 6) At CM-IRIS Event (n = 6) P Valueb
Monocytes, % 1.5 (0.7–2.0) 0.6 (0.2–1.1) .06
Monocyte subsets, %
 Classic (CD14++CD16−) 75.0 (69.6–89.7) 13.5 (0.0–26.3) .06
 Intermediate (CD14++CD16+) 22.5 (10.0–23.9) 73.6 (47.9–92.3)
.03c
 Nonclassic (CD14+CD16++) 2.3 (0.2–5.3) 6. 2 (3.7–23.9) .56
PD-L1 expression, %
 All monocytes 68.8 (30.1–97.0) 96.9 (93.0–100.0) .09
 Classic 62.4 (27.9–96.6) 82.2 (33.9–95.5) >.99
 Intermediate 86.0 (48.9–97.2) 98.2 (96.0–100.0) .06
 Nonclassic 78.9 (50.0–97.3) 98.0 (94.6–100.0) .06
Abbreviations: CM, cryptococcal meningitis; CSF, cerebrospinal fluid; IRIS, immune reconstitution inflammatory syndrome; PD-L1, programmed 
death ligand 1.
a
Data represent medians (interquartile ranges).
b
Median values were compared using a signed rank test for paired observations.
cSignificant difference (P < .05).
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